myrtenal has been researched along with Carcinogenesis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, EK; Ezz, MK; Farrag, MA; Ibrahim, NK | 1 |
| Lingaiah, HB; Natarajan, N; Periyasamy, BM; Srinivasan, P; Thamaraiselvan, R | 1 |
2 other study(ies) available for myrtenal and Carcinogenesis
| Article | Year |
|---|---|
Chemopreventive Potential of Myrtenal against Nitrosamine-Initiated, Radiation-Promoted Rat Bladder Carcinogenesis.
Topics: Animals; Bicyclic Monoterpenes; Butylhydroxybutylnitrosamine; Carcinogenesis; Carcinogens; Nitrosamines; Rats; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |
Myrtenal ameliorates diethylnitrosamine-induced hepatocarcinogenesis through the activation of tumor suppressor protein p53 and regulation of lysosomal and mitochondrial enzymes.
Topics: Animals; Antineoplastic Agents; Bicyclic Monoterpenes; Carbohydrate Metabolism; Carcinogenesis; Citric Acid Cycle; Diethylnitrosamine; Gluconeogenesis; Liver Neoplasms, Experimental; Lysosomes; Male; Mitochondria; Rats, Wistar; RNA, Messenger; Terpenes; Tumor Suppressor Protein p53 | 2013 |